GSK Consumer Healthcare Announces Completion of Solar Panel Project for Oak Hill Site in Partnership with Ameresco
The comprehensive solar panel project is designed to generate electricity equivalent to more than 70% of the Oak Hill site’s annual usage and reduce its carbon footprint by 60%
FRAMINGHAM, Mass. & OAK HILL, N.Y.–(BUSINESS WIRE)–#carbonreduction–GlaxoSmithKline (GSK) Consumer Healthcare and Ameresco, Inc., (NYSE: AMRC), a leading cleantech integrator specializing in energy efficiency and renewable energy, today announced the completion of a comprehensive solar panel project to serve GSK Consumer Healthcare’s Oak Hill, New York site. The project enables GSK Consumer Healthcare to reduce its carbon emissions.
Located in the scenic Catskill Mountains, the solar project near the Oak Hill site, which produces some of GSK Consumer Healthcare’s iconic oral health brands including Sensodyne, Pronamel, and parodontax for the US and Canadian markets, comprises over 17,000 modules with an estimated electricity generation capacity of 6.9 MW DC. This installation is designed to generate electricity equivalent to more than 70% of the Oak Hill site’s annual usage and reduce its carbon footprint by 60%.
“The completion of this project marks a pivotal moment for us at GSK Consumer Healthcare, as a continued step in the right direction for enacting real change that reduces our environmental impact and helps us deliver on our larger sustainability initiatives,” said Mike Allen, Sustainability Lead Consumer Health Supply Chain, GSK Consumer Healthcare. “The Oak Hill site is the 12th solar investment project for GSK and our Consumer Healthcare business, and we plan to implement additional major solar and wind energy investments in the UK and US to set us on track for 100% renewable electricity by 2025. We are thrilled to share news of this exciting milestone that we’ve reached working together with our partners and are committed and excited to continue building a more sustainable future.”
As the designated off-taker of the clean energy generated at the solar site, the completed project demonstrates GSK Consumer Healthcare’s larger ongoing commitment to its sustainability goals of reducing its Scope 1 and 2 carbon emissions by 100% by 2030.
“In order to form a more sustainable world, we need to work collaboratively with major corporations to implement energy-efficient solutions. I’m so thankful that we were able to work with an organization like GSK Consumer Healthcare, that has set forth aggressive goals for its future and truly understands the need to implement renewable technologies at a grand scale,” said Pete Christakis, Senior Vice President, Ameresco.
Project construction was completed in April 2022.
For more information on GSK Consumer Healthcare’s environmental commitments, visit www.gsk.com/en-gb/responsibility/environment/. To learn more about the solar power solutions for commercial and industrial project offered by Ameresco, visit https://www.ameresco.com/solution-solar-power/.
About Ameresco, Inc.
Founded in 2000, Ameresco, Inc. (NYSE:AMRC) is a leading cleantech integrator and renewable energy asset developer, owner and operator. Our comprehensive portfolio includes energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions delivered to clients throughout North America and Europe. Ameresco’s sustainability services in support of clients’ pursuit of Net Zero include upgrades to a facility’s energy infrastructure and the development, construction, and operation of distributed energy resources. Ameresco has successfully completed energy saving, environmentally responsible projects with Federal, state and local governments, healthcare and educational institutions, housing authorities, and commercial and industrial customers. With its corporate headquarters in Framingham, MA, Ameresco has more than 1,000 employees providing local expertise in the United States, Canada, and Europe. For more information, visit www.ameresco.com.
About GSK Consumer Healthcare
GSK Consumer Healthcare combines science and consumer insights to create innovative world-class health care brands that consumers trust and experts recommend for oral health, pain relief, respiratory and wellness. For further information please visit www.gsk.com.
The announcement of achieving commercial operations for an energy asset is not necessarily indicative of the timing or amount of revenue from the energy asset, of the company’s overall revenue for any particular period or of trends in the company’s overall total assets in development or operation. This project was included in our previously reported assets in development as of December 31, 2021.
Contacts
Media:
Ameresco: Leila Dillon, 508-661-2264, news@ameresco.com
GSK Consumer Healthcare: Sarah Miller, 845-324-2491, sarah.2.miller@gsk.com
